Purpose: This study aimed to evaluate the efficacy of robot-assisted gait training (RAGT) in older patients with neurological gait disorder accompanied by various comorbidities.
Materials And Methods: We included Individuals aged ≥65 years with degenerative brain diseases or stroke causing gait disorders for >6 months in open-label, a pilot study. RAGT was performed for 30 min/day, 2 days/week for 12 weeks. The intensity was set to 60% of the individual's heart rate maximum reserve. Primary outcome measures were the Timed Up and Go (TUG) test and Berg Balance Scale (BBS). Secondary outcomes included Beck Depression Inventory (BDI), Short Form-36 (SF-36), and evaluation of satisfaction.
Results: Thirteen participants completed 24 sessions. Neurological diseases included stroke ( = 7) and Parkinson's disease ( = 6); all patients had at least two other diseases. After RAGT, TUG test results significantly improved, and BBS scores increased. Furthermore, BDI scores decreased, and scores of social functioning and mental health domain in the SF-36 increased. Participants rated high scores on satisfaction of RAGT.
Conclusions: Our finding showed that RAGT is a safe and effective intervention for enhancing physical function, improving quality of life, and reducing depression levels in older patients with neurological gait disorder accompanied by various comorbidities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/0361073X.2025.2459546 | DOI Listing |
JMIR Form Res
March 2025
Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States.
Background: Screening for cognitive impairment in primary care is important, yet primary care physicians (PCPs) report conducting routine cognitive assessments for less than half of patients older than 60 years of age. Linus Health's Core Cognitive Evaluation (CCE), a tablet-based digital cognitive assessment, has been used for the detection of cognitive impairment, but its application in primary care is not yet studied.
Objective: This study aimed to explore the integration of CCE implementation in a primary care setting.
J Infect Dis
March 2025
Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor - Albert Chenevier, Assistance Publique-Hôpitaux de Paris (AP-HP), 94010 Créteil, France.
Background: Respiratory syncytial virus (RSV) is one of the deadliest respiratory viruses. There is a need to better identify prognostic factors in RSV-infected patients, particularly those requiring intensive care unit (ICU) admission, with a focus on immunosuppressed patients.
Methods: Multicenter, retrospective cohort study of RSV-infected adults hospitalized in 17 ICUs in the Great Paris area between 08/01/2017 and 05/01/2023.
J Am Acad Orthop Surg
March 2025
From the Department of Orthopaedics, Denver Health Medical Center, University of Colorado School of Medicine, Denver, CO (Ward), and the Department of Orthopaedics, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA (Parry).
Introduction: Excessive lag screw sliding after cephalomedullary nail fixation of intertrochanteric fractures can be problematic. Set screws are typically inserted to engage the lag screw and backed off to allow for sliding. The purpose of this study was to determine whether statically locking set screws affected lag screw sliding or cutout.
View Article and Find Full Text PDFEar Nose Throat J
March 2025
Department of Otorhinolaryngology, Tahar Sfar Hospital, Mahdia, Tunisia.
To describe the clinical and therapeutic features of fungal necrotizing otitis externa (NOE) as well as to identify the predictive factors of complications. This retrospective and monocentric study included 15 cases of fungal NOE treated in our ENT department between 2006 and 2024. Clinical, biological, microbiological, and imaging data were collected and evaluated.
View Article and Find Full Text PDFJ Infus Nurs
March 2025
Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!